The Jammu & Kashmir and Ladakh High Court affirmed that safe medicines constitute a fundamental right under Article 21, reinforcing the right to health. While refusing to dismiss criminal proceedings against three directors of Corona Remedies, the court highlighted public health implications.
Key Takeaways
- Safe medicines recognized as a fundamental right
- Criminal proceedings against directors remain active
- High Court links health to constitutional protection
The Jammu and Kashmir and Ladakh High Court stated that the right to safe medicines is not merely a consumer choice but a component of the right to life under Article 21. This observation came as the court declined to set aside criminal proceedings against three directors of Corona Remedies Private Limited.
The case originated from a batch of Locipil tablets produced in September 2015, which a government analyst declared “Not of Standard Quality.” Following this, the Central Drugs Standard Control Organisation and the chief judicial magistrate initiated action under Sections 18(a)(i) and 27(d) of the Drugs and Cosmetics Act, 1940.
Why This Matters
BozokMedia analysis shows that this ruling could tighten quality‑control standards across the pharmaceutical sector, guaranteeing consumers the constitutional right to safe medication. The judgment may serve as a precedent for future cases involving public‑health concerns.
"Recognizing safe medicines as a fundamental right elevates public health to a constitutional priority," said health‑law expert Dr. Rajesh Singh.
Frequently Asked Questions
Question 1: Can directors be held personally liable for sub‑standard drugs?
Answer: The court clarified that liability depends on evidence proving they were “in charge of” the company’s operations, not merely their titles.
Question 2: What impact will this decision have on the pharmaceutical industry?
Answer: It is expected to compel manufacturers to adhere strictly to quality standards, reinforcing consumer protection and public health safeguards.
